Replies to post #1853 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Cramer thinks that Abbvie's Richard Gonzalez will cut Botox prices to compete with RVNC…

Cramer is off-base, IMO. RVNC is planning to price Daxi at a premium to Botox (on a per-treatment basis, but not necessarily on a per-annum basis); hence, I doubt that ABBV will respond by price-cutting when Botox will already have a price advantage on a per-treatment basis.